Welcome to "Drug Diaries," the podcast exploring pharmaceuticals, life sciences, and biotechnology. Host Kaushik Trivedi, with over two decades of industry experience, shares his expertise. Kaushik has worked with IQVIA, Cognizant, Wipro, and more, and holds degrees in pharmaceutical chemistry, marketing, and advertising. Kaushik's expertise spans: - Data-Driven GTM & Customer Engagement - CRM, Marketing Cloud, SFE, & Commercial Analytics - AI/ML/NLP in Life Sciences - Population Health Management - IoT & Connected Devices - Content Production & MLR Approval - R&D, Clinical, Pharmacovigilance, Medical, & Regulatory - Business Transformation "Drug Diaries" covers research, drug discovery, AI in health, GTM strategies, customer engagement, analytics, patient safety, product engineering, and more. Join Kaushik for insights and discussions on the ever-evolving pharma and biotech landscape. Each episode is a deep dive into the industry's heart. Welcome to "Drug Diaries."
Pitch Analysis
Required Pod Score for this show. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Public web form
Booking probability
32%
Guest openness
Selective
80/100
Required Score
Sign up to generate a grounded pitch for Drug Diaries.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Episode #79
Why 90% Of Cancer Treatments Fail – Are We Looking In The Wrong Place?
Aug 29, 202651 minS1
In this conversation, Kaushik Trivedi interviews Professor Andrew Beggs, a pioneering figure in cancer genetics and surgery. They discuss the traditional approaches to cancer treatment and how Andrew's dual role as a surgeon and scientist allows him to bridge the gap between immediate patient care and long-term research. Andrew shares his personal journey, including moments of self-doubt, the emotional challenges of balancing surgery and research, and the sacrifices made in pursuit of excellence. The conversation also touches on the evolution of cancer understanding, the importance of collaboration in research, and the future of cancer treatment through genomics and immunotherapy. In this conversation, Andrew Beggs discusses the transformative potential of liquid biopsies, advancements in precision therapy, and the future of organoid technology in cancer treatment. He highlights the challenges in organoid culture and the revolutionary impact of long-read genomic sequencing. The discussion also covers the role of AI in cancer diagnostics, the emerging innovation hub in the West Midlands, and the barriers to biotech advancement in the UK. Finally, they touch on the significance of Life Sciences Week as a platform for fostering collaboration and innovation in the healthcare sector. Exclusive Access: Life Sciences Week 2026 (#LSW26)!We are thrilled to announce that Drug Diaries is partnering with Life Sciences Week 2026 (21–25 September 2026), the UK’s premier gathering for biotech, pharma, med-tech, AI, and healthcare policy leaders! Join 3,000+ industry pioneers, policymakers, and investors as we dive deep into the future of healthcare innovation. Seats are filling fast—secure your spot today with our exclusive community discount! ️ Register Now: https://lifesciencesweek.co.uk/attend/ ⚡ Exclusive Discount Code: DRUGDIARIES10 (Use at checkout for an exclusive discount!)Don't wait—claim your ticket now and be part of the national conversation shaping life sciences! Chapters 00:00 Introduction to Andrew Beggs and his dual role in surgery and science 02:44 Andrew's motivation for combining surgery with genomics research 04:23 Early influences and the evolution of Andrew’s career 06:31 Overcoming self-doubt and career setbacks 09:48 Spark for cancer genetics and core beliefs changed 12:24 Handling emotional challenges of patient outcomes 14:29 Balancing clinical intensity with scientific research 16:01 Personal sacrifices and leadership in high-stakes environments 17:17 Lessons on leading multidisciplinary teams 21:19 Explaining cancer heterogeneity to a child 22:38 Progress in cancer genomics and immunotherapy 24:06 Liquid biopsy and its revolutionary potential 27:25 Organoids and personalized drug testing 34:48 Advances in long-read sequencing technology 37:50 AI in cancer diagnostics and research 40:48 Predicting immune responses with AI and genomics 42:22 West Midlands as a biotech innovation hub 47:43 Future of cancer treatment and diagnostic breakthroughs in 10 years Get vidIQ to grow your channel faster! https://vidiq.com/DrugDiaries
The Man Who Saved the $50 Billion Drug (Against His Bosses)
Aug 20, 20261h 13mS1
How one pharmaceutical development project generated 50 billion dollars despite management trying to kill it. See the high-stakes reality. In this episode, Dr. David Brown shares his 52-year journey in drug discovery, the transformative potential of AI in medicine, and the urgent need for the pharmaceutical industry to embrace paradigm shifts to reduce human suffering. You will hear the inside perspective of a clinical development committee meeting where the project was faced with a three-month deadline to prove efficacy or face total termination. This is for anyone interested in the friction between medical research and corporate budget constraints. Learn how drug discovery survives when budgets are cut to zero and leadership demands immediate results. We examine the tension of professional life when your career hinges on proving the viability of a vital medical treatment. Understand the pressure of navigating complex clinical trials while your own company actively attempts to shut you down. Subscribe for weekly career breakdowns and tell me, have you ever had to fight for a project you believed in against all odds? Chapters 0:00 The $50 Billion Discovery That Almost Never Was 5:05 From Punch Cards to AI-Driven Medicine 9:10 Why AI Must Be the Foundation, Not a Bolt-On 14:07 The Stagnation of Big Pharma's Financial Engine 18:06 The 90-Day Thread: A Project Hanging by a Wire 25:03 The Lightbulb Moment: Connecting the Dots 35:55 Navigating Power Plays in Legacy Organizations 42:21 Mapping Mountains and Valleys with AI Get vidIQ to grow your channel faster! https://vidiq.com/DrugDiaries
Is West Midlands the next pharma innovation powerhub?
Aug 4, 20261h 18mS1
In this episode, Kaushik Trivedi interviews Professor Neil Hanley about the transformative healthcare innovations happening in the West Midlands, UK. They explore regional collaboration, cutting-edge research, and the future of data-driven medicine. As a thank you to the Drug Diaries Podcast community, I am pleased to share an exclusive 10% discount for Life Sciences Week 2026. Use code: DRUGDIARIES10 https://lifesciencesweek.co.uk/conference-launch-tickets/ Chapters 00:00 Introduction to the West Midlands healthcare revolution 01:19 Neil Hanley's role in shaping UK health innovation 03:10 Neil Hanley's early career and scientific inspiration 11:13 The concept of the golden parallelogram in UK science 14:41 The strategic importance of Birmingham's diverse healthcare ecosystem 20:58 The Birmingham Health Innovation Campus and its facilities 25:31 Co-locating startups, scientists, and healthcare providers 32:44 Data-driven healthcare and AI in preventative medicine 38:44 Future directions in aging, longevity, and gene therapy 48:53 Neil Hanley's legacy and vision for Birmingham Get vidIQ to grow your channel faster! https://vidiq.com/DrugDiaries
This discussion breaks down the current state of artificial intelligence integration within the pharmaceutical sector. We examine why scaling AI solutions is a major hurdle for many organisations and how to overcome the gap between technical capability and actual deployment. This is essential viewing for anyone trying to navigate the complexities of adopting advanced technologies in a highly regulated environment. If you are a vendor selling to pharma, the advice provided here is critical. We discuss why generic pitches fail and why presenting concrete AI business cases is the only way to secure buy-in from stakeholders. Instead of focusing on hype, learn how to demonstrate measurable ROI and operational efficiency to decision-makers who need to see real-world results before committing to new partnerships. Subscribe for weekly B2B strategy breakdowns, and comment below on which industry sector you want us to analyse next. Chapters 00:00 Introduction to AI's role in healthcare decision-making 02:28 Flora Eduard's background and industry transformation 06:40 The surprising lack of data use in pharma decision-making 08:11 Leadership principles Flora refuses to compromise 12:45 Cultural insights from working across countries 16:08 Biggest setbacks and lessons learned 22:39 Digital transformation vs. digitization 28:41 Current state of AI experimentation in pharma 31:52 Understanding agentic AI and its differences from traditional AI 34:45 The future of AI and how soon it will arrive 40:49 AI's potential to improve patient outcomes 45:33 Skills needed for future leaders in the AI era 01:10:10 The future of pharma in 2035 01:11:48 Rapid fire insights and predictions Get vidIQ to grow your channel faster! https://vidiq.com/DrugDiaries Learn how to approach AI in pharma by focusing on proven business cases rather than theoretical potential. Discover what works today.
Stop sending mass emails that land you on a blacklist. Learn why mass email practices hurt healthcare communication and how Maya offers a better way. Sending unsolicited bulk emails to entire departments is a fast way to get your domain blocked. This video explains the mechanics behind vendor blacklisting and why standard mass outreach strategies often fail in clinical environments. If you are struggling with low engagement or deliverability issues, understanding these risks is the first step toward fixing your outreach. We discuss the concept of Maya as a potential path forward. The core takeaway is that even the most advanced technical solutions fail if they do not fit the specific communication landscape of healthcare. We analyze why context and recipient relevance matter more than volume when you are trying to reach busy medical professionals. Subscribe for weekly email deliverability breakdowns, and comment below if you have ever faced a domain blacklist issue. keywords healthcare innovation, pharma digital transformation, content experience, AI in pharma, networking, pilot projects, healthcare technology key topics The importance of authentic human connection in healthcare Challenges and opportunities in pharma digital transformation The future of AI and agentic technology in healthcare Effective networking and relationship building in pharma Scaling pilots and proof of concepts for long-term success guest name: Gaurav Sanganee Chapters 00:00 The Crisis in Healthcare Communication 02:59 Breaking Away from Convention 05:25 The Role of Closing Delta and Relato 08:12 Navigating the Challenges of Pilots and Proof of Concepts 10:46 The Importance of Incremental Change 13:09 The Static Content Crisis in Pharma 15:41 The Future of Healthcare Communication 31:06 The Evolution of Content Delivery 35:44 Transforming Scientific Content Presentation 41:02 Embracing New Technologies in Pharma 47:30 The Future of Healthcare Tech 52:46 Rapid Fire Insights and Reflections Resources Founder - The MacDonald Story - https://www.imdb.com/title/tt0107048/ Maverick - https://www.imdb.com/title/tt1631867/ Relayto Content Experience Platform - https://relayto.com/ Closing Delta - https://www.linkedin.com/company/closing-delta/about/ Guest links LinkedIn: https://www.linkedin.com/in/gaurav-sanganee/ Get vidIQ to grow your channel faster! 🚀 https://vidiq.com/DrugDiaries
Every question we get asked before someone starts their trial.
If you have a concern about deliverability, AI quality, data privacy, or whether this will actually work for your specific situation, it's probably answered below.
What is the difference between Founder Solo and Founder Pro?
Founder Solo gives you 50 AI pitches per month using the credit model (Standard pitches cost 1 credit, Enriched pitches cost 2). Founder Pro raises that to 200 credits per month and adds full Booking Probability access, unlimited Magic Match, Apollo enrichment credits, and data export capabilities. Both plans use the same credit system, so you can stretch your monthly budget further by using Standard-mode drafting.
How do agency tiers work?
Agency tiers have no base fee. You pay per managed client and per talent profile. Agency Standard is $199 per client per month; Agency Pro is $399 per client per month. Both add $39 per talent profile per month. Your own team's user seats are always free.
What is a talent profile?
A talent profile represents one person (founder, executive, or spokesperson) you are booking onto podcasts. It includes their bio, topics, headshots, and outreach history. Team plans include 5 profiles; agency plans are pay-as-you-go.
Can I switch plans later?
Yes, at any time. Upgrades take effect immediately; downgrades apply at the end of the current billing period. Contact support if you need help migrating between plan families.
Do you offer a free trial?
Every paid plan includes a 15-day free trial. Your card is saved at signup but you will not be charged until day 16. Cancel any time from your dashboard.
What happens if I cancel?
You keep access until the end of your current billing period. No charges after that. Your data is retained for 30 days in case you reactivate.
Is the 20% annual discount automatic?
Yes. Select Annual on the pricing toggle and the discounted price is applied automatically at checkout. The annual price shown is the full year cost.
What if I have more than 50 profiles or 20 clients?
That is our Enterprise tier. Contact our sales team and we will build a custom plan with volume pricing, a dedicated account manager, and SLA guarantees.
